semaglutide patent expiry europe Off-patent in 2026: the next revolution in anti-obesity medications As the patent for semaglutide,

Originally developed to manage blood sugar in people with diabetes, it now also helps people who are overweight or obese

The best time to establish GLP-1 care with insurance coverage is before the market restructures around biosimilars

When you move, your muscles burn energy, and a significant portion of that energy is released as heat

Please visit Ozempic.com or Wegovy.com for a full list of important safety information for these medications

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both approved for diabetes, not weight loss specifically

Individual factors such as weight-loss goals, existing medical conditions, budget, and local availability determine the best option